Literature DB >> 3103433

Rationale for diphosphonate therapy in hypercalcemia of malignancy. Introduction.

R E Canfield.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3103433     DOI： 10.1016/0002-9343(87)90482-7

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  4 in total

1.  Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate.

Authors:  B R Boudailliez; B J Pautard; J L Sebert; O Kremp; C X Piussan
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

2.  Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?

Authors:  T Klenner; F Wingen; B K Keppler; B Krempien; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat.

Authors:  T Klenner; F Wingen; B Keppler; P Valenzuela-Paz; F Amelung; D Schmähl
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

4.  Recovery from pamidronate (APD): a two-year study in the dog.

Authors:  M D Grynpas; M Kasra; M Dumitriu; R Nespeca; J M Very; B P Mertz
Journal:  Calcif Tissue Int       Date:  1994-10       Impact factor: 4.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.